Tempus AI: Clinical Trials

4 trials sponsored by Tempus AI, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Recruiting 1, Terminated 1
Phase 12Active not recruiting 1, Recruiting 1

Follow Tempus AI: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer
Phase 1 / Phase 2RecruitingA2 Biotherapeutics Inc.4742024-04-032026-06-12
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor
Phase 1 / Phase 2Active not recruitingA2 Biotherapeutics Inc.1602023-04-282025-04-25
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Niraparib - Solid Tumor, Breast Tumor
Phase 2TerminatedTempus AI222022-03-152025-10-29
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy - Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Phase 2Active not recruitingM.D. Anderson Cancer Center13622014-05-132026-08-10

Conditions studied

Pancreatic Neoplasms (3)  ·  Recurrence (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colonic Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Melanoma (1)  ·  Mesothelioma (1)  ·  Mesothelioma, Malignant (1)

Interventions

niraparib (1)

Countries

United States (4)

Top investigators

Apostolia M Tsimberidou (1)  ·  Eric Ng, MD (1)  ·  John Welch, MD, PhD (1)  ·  Virginia Rhodes (1)

Results publications

PMID 27457512, PMID 33995588, PMID 36302890